Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €55.20 EUR
Change Today +0.94 / 1.74%
Volume 0.0
SG7 On Other Exchanges
Symbol
Exchange
Frankfurt
As of 10:10 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

sage therapeutics inc (SG7) Snapshot

Open
€54.65
Previous Close
€54.26
Day High
€55.20
Day Low
€54.04
52 Week High
04/16/15 - €57.36
52 Week Low
07/29/14 - €18.70
Market Cap
1.6B
Average Volume 10 Days
44.4
EPS TTM
--
Shares Outstanding
28.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAGE THERAPEUTICS INC (SG7)

sage therapeutics inc (SG7) Related Businessweek News

No Related Businessweek News Found

sage therapeutics inc (SG7) Details

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat life-threatening and rare central nervous system disorders. The company’s lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its pipeline also includes second-generation molecules, such as SAGE-217, an oral therapy for orphan genetic epilepsies; and SAGE-689, an adjunctive intravenous second-line therapy for the treatment of refractory status epilepticus. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.

31 Employees
Last Reported Date: 04/15/15
Founded in 2010

sage therapeutics inc (SG7) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $550.0K
Chief Medical Officer
Total Annual Compensation: $390.0K
Chief Scientific Officer
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

sage therapeutics inc (SG7) Key Developments

SAGE Therapeutics Announces an End-Of-Phase 2 Meeting with the U.S. Food and Drug Administration

SAGE Therapeutics announced an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) yielded general agreement on the design and key elements of a Phase 3 clinical program for its SAGE-547 in the treatment of patients with super-refractory status epilepticus. SAGE believes the results from the Phase 3 clinical trial, along with other clinical data obtained from the SAGE-547 development program, could form the basis of a New Drug Application (NDA) submission for SAGE-547. The planned primary endpoint of the Phase 3 clinical trial will be successful resolution of status epilepticus after weaning the patient off all third-line anti-seizure agents, and SAGE-547 or placebo, without resumption within 24 hours after completion of blinded SAGE-547 or placebo administration. Secondary endpoints are expected to explore the rate of recovery, regaining of consciousness, mental status and functional outcome. SAGE anticipates reporting clinical data from the Phase 1/2 open-label clinical trial of SAGE-547 at the Antiepileptic Drug and Device Trials XIII Conference, taking place May 13-15.

Sage Therapeutics, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Sage Therapeutics, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported loss from operations of $33,810,000 compared to $18,279,000 a year ago. Net loss and comprehensive loss was $33,811,000 compared to $18,281,000 a year ago. Net loss attributable to common stockholders was $36,105,000 or $1.67 per basic and diluted share compared to $18,288,000 or $12.26 per basic and diluted share a year ago.

Sage Therapeutics, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

Sage Therapeutics, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SG7:GR €55.20 EUR +0.94

SG7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SG7.
View Industry Companies
 

Industry Analysis

SG7

Industry Average

Valuation SG7 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 12.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGE THERAPEUTICS INC, please visit www.sagerx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.